Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Heeschen
Christopher Heeschen, Munich DE
| Patent application number | Description | Published |
|---|---|---|
| 20080267927 | Methods for improving cell therapy and tissue regeneration in patients with cardiovascular diseases by means of shockwaves - Improving cell therapy and tissue regeneration in a patient suffering from a cardiovascular or a neurological disease by treating a tissue of the patient with shock waves and/or applying to the patient a therapeutically effective amount of stem cells and/or progenitor cells. Such treatment increases expression of chemoattractants, pro-angiogenic factors, and pro-survival factors. The chemoattractants can be, for example, vascular endothelial growth factor (VEGF) or stromal cell derived factor 1 (SDF-1). For example, the treated tissue can be located in the patient's heart or in a skeletal muscle of the patient, and the shock waves can be extracorporeal shock waves (ESW) or intracorporeal shock waves. The cardiovascular disease can have an ischemic or non-ischemic etiology. For example, the cardiovascular disease can be a myocardial infarction, ischemic cardiomyopathy, or a dilatative cardiomyopathy. For example, the neurological disease can be a peripheral neuropathy or neuropathic pain. | 10-30-2008 |
| 20090155827 | PIGF and FLT-1 as Prognostic Parameters for Cardiovascular Diseases - The present invention refers to a use of an ex vivo method comprising the determination of PlGF and sFlt-1 in a sample for diagnosis, risk stratification and/or monitoring of a vascular disease with atherosclerotic etiology, in particular a coronary heart disease such a unstable angina pectoris or myocardial infarction, and/or for estimation of the probability of developing such a disease, as well as for identification of a patient supposed to benefit from a therapy by agents reducing the risk for a cardiovascular disease. In the method (i) a ratio of [PlGF=high:sFlt-1=low], and/or (ii) a PlGF concentration in the upper two tertiles of a reference collective, and an sFlt-1 concentration in the lower tertile of the reference collective, and/or (iii) a PlGF result above a PlGF reference value, and an sFlt-1 result below an sFlt-1-reference value indicate an elevated probability for an adverse event. The present invention also refers to the used method. The present invention further refers to a diagnostic kit and its use as well as to an assay element and its use. | 06-18-2009 |
Christopher Heeschen, Frankfurt DE
| Patent application number | Description | Published |
|---|---|---|
| 20080242591 | METHODS OF REDUCING ANGIOGENESIS - The present invention provides methods of reducing angiogenesis in an individual. The methods generally involve administering to the individual an effective amount of a nicotinic acetyl choline receptor antagonist. The methods are useful to treat conditions associated with or resulting from angiogenesis, particularly pathological angiogenesis. The invention further provides methods of treating a condition associated with or resulting from angiogenesis. | 10-02-2008 |
Christopher Heeschen, Menlo Park, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20110124688 | NICOTINE RECEPTOR AGONISTS IN STEM CELL AND PROGENITOR CELL RECRUITMENT - The present invention features methods for recruitment of bone marrow-derived stem cells (e.g., endothelial cell precursors, hematopoietic stem cells) by administration of nicotine or other nicotine receptor agonist. The methods of the invention can be used in, for example, treatment of conditions amenable to treatment by recruitment of bone marrow-derived stem cells (e.g., neutropenia). | 05-26-2011 |
Christopher Heeschen, Madrid ES
| Patent application number | Description | Published |
|---|---|---|
| 20110151020 | ACTIVE SUBSTANCE COMBINATION WITH GEMCITABINE FOR THE TREATMENT OF EPITHELIAL CANCER - The present invention refers to active substance combinations comprising of a nucleoside analog or antimetabolic agent like Gemcitabine, and either a Nodal/Activin inhibitor or a SHH-Inhibitor and an mTOR-inhibitor, medicaments comprising the same and the use of the active substance combinations in the treatment of cancer, especially of epithelial cancer. | 06-23-2011 |
David R. Heeschen, Coral Springs, FL US
| Patent application number | Description | Published |
|---|---|---|
| 20090275355 | METHOD AND APPARATUS FOR CONTROLLING POWER AMONG MODEMS IN A MULTI-MODE MOBILE COMMUNICATION DEVICE - A multi-mode communication device ( | 11-05-2009 |
William A. Heeschen, Midland, MI US
| Patent application number | Description | Published |
|---|---|---|
| 20090059218 | STABLE TURBIDITY CALIBRATION STANDARDS - The present invention relates to a turbidity calibration standard comprising: a number of from 1 to 5 sequentially-interfaced layers, wherein each layer independently comprises a light-permeable polymer or light-permeable interpolymer; a measured light transmission modulating amount of at least one light transmission modulator, which is distributed in any one or more of the layers; and a light-permeable container, which contains the layers and the at least one light transmission modulator. Also, the invention relates to methods of making and using the standard, and kits comprising the standard. | 03-05-2009 |
| 20100118130 | DIGITAL IMAGING SYSTEM - The invention is an image capturing device comprising a lens to capture the image of the one or more samples which are located in an image capturing chamber, a nest receptacle to hold the one or more samples during imaging, and at least one illuminating source to illuminate the one or more samples. The chamber, lighting and nest receptacle are configured to minimize undesired reflections and improve the image quality. | 05-13-2010 |
| 20110028577 | POSITIVE SKEW STYRENE-ACRYLONITRILE COPOLYMER FOAM - Prepare a polymeric foam from a foamable polymer composition containing a thermoplastic polymer composition and a blowing agent wherein 75 percent or more by weight of all non-halogenated polymers in the foamable polymer composition is a styrene-acrylonitrile copolymer composition having a polymerized acrylonitrile content distribution with a positive skew in a copolymerized AN content distribution and a positive percent difference between the mean and the median copolymerized AN content distribution. | 02-03-2011 |